94 results about "Neutrophile" patented technology

Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of the human G-CSF native sequence and analogues thereof. These novel site-specific mono-conjugated derivatives are recommended for therapeutic use since they are stable in solution and exhibit significant biological activity in vitro and a longer bloodstream half-life, as compared to the non-conjugated protein, with a consequent prolonged pharmacological activity.

Methods for diagnosing renal disorders by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.

Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.

The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g. be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g. be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate, which has a reduced in vitro bioactivity compared to hG-CSF, has one or more improved properties such as increased biological half-life and increased stimulation of neutrophils.

The invention relates to a method for diagnosing, evaluating or testing a cancer and foreseeing the severity of the cancer. The testing method comprises the following steps: an antibody of anti-human tropic neutrophil gelatinase-associated lipocalin (NGAL) is reacted with the human NGAL of a specimen to be tested to form a compound which causes turbidity change; light protection intensity or light scattering intensity is used for presenting the change; the human NGAL content of the specimen to be tested is tested through a standard curve of the concentration of human NGAL standard to relevant light protection intensity or light scattering intensity; and finally the cancer severity is measured based on the tested NGAL content. The method has the advantages of high flexibility, high recovery and good repetitiveness, determines a testing method with great convenience, good repetitiveness and strong suitability for the NGAL in urine or blood plasma of a cancer patient, and provides possibility for the clinical directive function of human NGAL and further research of the functions of the human NGAL.

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention relates to an immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and a preparation method thereof; an application liquid bottle, an antibody suspending liquid bottle and a standard substance bottle are placed in a box body; application liquid is arranged in the application liquid bottle, and comprises the following components of: 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative, 1 percent to 20 percent of sodium chloride and 20mmol/l to 200mmol/l of buffer solution; the antibody suspending liquid bottle contains emulsion suspension which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, and the emulsion suspension has the following components of: 0.05 percent to 0.5 percent of emulsion which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative and 20mmol/l to 200mmol/l of buffer solution; and the standard substance bottle contains the standard substances of the lipid carrier protein related to the neutrophils gelatinase. According to the invention, the mass quantitative detection on a biochemical instrument is realized.

Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.

The invention belongs to the field of natural medicinal chemistry, in particular to separation and extraction of natural anti-inflammatory drug molecules and an application thereof. The method comprises the following steps of extracting by acidic ethanol, decompressing and concentrating, adding water for dissolving, loading a sample in XAD-7 macroporous resin, eluting, collecting and concentrating, freeze-drying to extract the mangosteen pericarp anthocyanin. Experimental results show that mouse peritoneal fluid neutrophil exudation can be effectively inhibited after the mangosteen pericarp anthocyanin is injected into caudal vein of the mouse, the inhibition ratios are respectively 34%, 77% and 94% while the dosages are respectively 0.01, 0.1 and 1mg/ml. A laminar experiment using an in-vitro simulated capillary proves that the adhesion inhibition ratios of the mangosteen pericarp anthocyanin on neutrophil are respectively 45%, 71% and 89% while the dosages are respectively 0.01, 0.1 and 1mg/ml. Therefore, the anti-inflammatory activity of the mangosteen pericarp anthocyanin is proved, and the mangosteen pericarp anthocyanin as a novel anti-inflammatory drug has good application prospect.

The invention relates to the technical field of cosmetic efficacy evaluation, and discloses a method for evaluating the efficacy of cosmetics for relieving or repairing skin inflammation in order to solve the problems that in an existing cosmetic skin inflammation relieving evaluation method, the subjectivity of evaluation index selection and treatment is high, and subjective factor interference is brought to an evaluation result. The method comprises the following steps: taking zebra fish as a test object, setting a normal control group, a model control group and a test group, culturing underthe same condition, photographing under a fluorescence microscope, storing a picture, and counting the number of neutrophils in a skin inflammation part of the zebra fish by adopting image processingsoftware based on a statistical method; and then calculating the inflammation relieving or repairing effect (%). Compared with the prior art, the evaluation index data is selected and analyzed by means of instruments and software, and the evaluation result can be quantified; the zebra fish breeding cost is low, the breeding period is short, the breeding amount is large, and the evaluation methodhas the advantages of being efficient, rapid and low in cost.

The invention relates to an establishing method of a neutropenia atherosclerosis model rat, and belongs to the technical field of genetic engineering and genetic modification. A first neutropenia atherosclerosis rat genetic model is established by introducing the Gfi1 point mutation into an ApoE-knocked-out rat gemone for the first time. It is proved through experiments that in the model rat, atherosclerosis plaque is remarkably reduced and atherosclerosis symptoms are remarkably relieved; it is shown that the neutropenia atherosclerosis model rat is successfully established and the atherosclerosis lesion degree can be relieved by neutropenia. The obtained neutropenia cocurrent atherosclerosis model rat has quite important potential application value in the disclosing of the effects of neutrophils on forming and repairing of atherosclerosis and in the diagnosis and treatment of atherosclerosis.

The invention discloses a pyrimidine-2, 4-diamine compound and a preparation method and application thereof, and relates to the technical field of medicinal chemistry, the pyrimidine-2, 4-diamine compound can be used for biological or pharmacological phenomena, cathepsin C participated signal channel conduction research, and evaluation of a novel cathepsin C inhibitor; in addition, through in-vitro and in-vivo anti-cathepsin C activity screening, the results show that the compound has relatively strong inhibitory activity on cathepsin C; through in-vivo anti-neutrophil serine protease activity screening, the result shows that the compound has relatively strong inhibitory activity on neutrophil serine protease; in-vivo anti-inflammatory activity screening results show that the compound has an effective treatment effect on an inflammatory disease model; meanwhile, the toxicity is low, and the application prospect is good.

Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

The invention discloses a neutrophil gelatinase-associated lipocalin detection kit which comprises seven storage assemblies, wherein the storage assemblies are respectively used for storing a neutrophil gelatinase-associated lipocalin (NGAL) calibration product, an NGAL quality control product, an enzyme conjugate working solution, a magnetic bead working solution, a cleaning solution, a substratesolution and a pretreatment reagent; the magnetic bead working solution contains carboxyl magnetic beads labeled with an NGAL antibody; and the magnetic bead working solution contains an anti-NGAL antibody labeled by alkaline phosphatase. The invention further discloses a detection method for detecting the neutrophil gelatinase-associated lipocalin. The detection kit disclosed by the invention has the lowest detection limit of 1ng/ml; and the linear range is 1-300ng/ml, the detection sensitivity is high, the linear range is wide, the detection duration is shortened to 15 minutes, and the detection steps are simplified.

The invention discloses an application of Necrostatin-1 as a neutrophile granulocyte apoptosis accelerant. Study on compound 5-(1H-benzpyrole-3-ylmethyl)-3-methyl-2-thioketone-4thioketone conducted by the inventor shows that except for the known function of inhibiting programmed necrosis, 5-(1H-benzpyrole-3-ylmethyl)-3-methyl-2-thioketone-4thioketone also has the effects of promoting the apoptosis of the neutrophile granulocyte, and treating neutrophile granulocyte apoptosis abnormity diseases by promoting the apoptosis of the neutrophile granulocyte, especially the acute lung injury caused by LPS. Molecules of 5-(1H-benzpyrole-3-ylmethyl)-3-methyl-2-thioketone-4thioketone are small, can be easily accepted by the mechanism, also can specifically act on neutrophile granulocyte to promote the apoptosis of the neutrophile granulocyte, and have no influences on the apoptosis of other cells.

The present invention provides an in vitro method for quantifying exposure to psychological stress which relies on measuring the retained ability of neutrophils, preferably neutrophils in a whole blood sample, to exhibit challenge-induced superoxide anion production. Using such methodology, coping capacity of individuals for particular psychological stressors may be assessed.

An assay test kit is used in a mouth rinse sample collection procedure involving collecting a mouth rinse sample from a patient. A neutrophil reactant diagnostic reagent is delivered to the rinse sample immediately after collection. Diagnostic reagents containing diammonium salts that are reactive with neutrophil enzymes are added to the sample to produce visually discernable colour change in the solution after a selected period of time. Most preferably, the reagents are selected to produce a colour change after a period of time. The reaction is then measured by comparing the resulting sample colour change by eye or mechanically to a standardized colour chart/swatch that correlates with predetermined neutrophil concentrations and/or periodontal disease levels.